Please login to the form below

pulmonary embolism

This page shows the latest pulmonary embolism news and features for those working in and with pharma, biotech and healthcare.

as pulmonary embolism (PE) or deep vein thrombosis (DVT) and an uncompetitive dose.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

baricitinib’s potential to cause side effects such as pulmonary embolism and venous thromboembolism.
AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

There was a fatality from a stroke in the trial in a patient, plus one case of a pulmonary embolism, although AbbVie said these occurred in at-risk patients.
Xarelto beats aspirin for recurrent blood clots

Janssen's parent company Johnson &Johnson (J&J) said in a statement that up to 10% of people who have suffered a VTE (usually a deep vein thrombosis or pulmonary embolism)
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE has backed Daiichi Sankyo's Lixiana (edoxaban) in final guidance as a treatment for adults with deep vein thrombosis and pulmonary embolism. ... NICE concluded that Lixiana was a cost-effective use of NHS resources for deep vein thrombosis (DVT) and
Daiichi’s new anticoagulant recommended by NICE

Specifically, in draft guidance NICE is minded to recommend Lixiana (edoxaban) as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more ... NICE has already recommended Lixiana for the

More from news
Approximately 4 fully matching, plus 55 partially matching documents found.

Modern anticoagulants threaten status quo

embolism in patients with AF and for the prevention of VTE in patients undergoing knee or hip replacement surgery. ... In one phase III trial, idrabiotaparinux sodium was non-inferior to warfarin in preventing the recurrent VTE at three months in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Add my company

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....